19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2523
HELPLINE: 1-877-530-0002



Facebook    

 

SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace

 

 

 

 


powered by centersite dot net
Child & Adolescent Development: Overview
Resources
Basic InformationMore InformationLatest News
A Good Night's Sleep Is Key to School SuccessHealth Tip: Helping Children Adjust to a MoveKids Often Prescribed Drugs 'Off-Label,' Raising ConcernsExperts' Guide to Trampoline SafetyDon't Let Kids Wander Alone in Parking LotsMost U.S. Parents Say Vaccination Should Be Requirement for School: PollIf a Child's Schoolwork Slips, Don't Rule Out Hearing LossNurturing Childhood Boosts Odds of a Happy Adult Life: StudyKids in Poor Neighborhoods Face Higher Odds for Obesity as AdultsA Prescription for Medicating Your Child SafelyIs a Charter School the Right Choice for Your Child?Health Tip: Mental Illness Warning SignsAn Easy Recipe for Healthier Back-to-School LunchesAHA News: Understanding Connection Between Poverty, Childhood Trauma and Heart DiseaseHealth Tip: Staying Well During the School YearBackpacks Shouldn't Be a Back-to-School Burden on HealthA Kid-Friendly Emergency Room Saves LivesMany Parents Would Switch Doctors Over Vaccination Policy, Poll FindsAs School Starts, Pack That Lunch With Nutritional Goodies5 Health Tips to Promote Back-to-School SuccessPot Poisonings Among Kids, Teens Double After Medical Marijuana Law PassedFor Kids Born With HIV, Taking Needed Meds Gets Harder With Age: StudyBuilding a Better BackpackKids Getting Too Many Opioids After TonsillectomyExplaining, Easing the Horror of Mass Shootings for Your KidsFor Kids With Asthma, Allergies, New School Year Can Bring Flare-UpsAnother Video Game Risk to Watch Out ForOlder Parents May Have Better Behaved KidsAre Too Many Kids Prescribed Antihistamines?Childhood Cancer Steals Over 11 Million Years of Healthy Life: StudyFamily Home, Football Field Most Dangerous Spots for Kids' Head InjuriesMost Airplanes Not Equipped With First Aid for KidsPlastics Chemicals Meant to Replace BPA May Not Be Any Safer for KidsWhat Happens to the Children When Parents Fight?Health Tip: Giving Medicine Safely to ChildrenHow to Make Your Child's Hospital Stay Safer, Less StressfulObesity May Boost Odds for MS in KidsHealth Tip: Diarrhea in KidsOpioid Epidemic Doubled Number of U.S. Kids Sent to Foster CareSwimming Lessons a Must for EveryoneHow to Help When Your Child Weighs Too MuchHave Kids, Buy More Produce?Zika's Damage Continues in Children Infected Before BirthCDC Warns of Start to 'Season' for Mysterious Paralyzing Illness in KidsParent Who Listens Can Help Kids Thrive Despite TraumaHealth Tip: Ear Piercing For KidsReacting Against a 'Too Clean' World, Some Parents Go Too Far the Other WaySurvey Urges Grandparents to Lock Down Their Meds When Kids VisitCalifornia Took on Anti-Vaxxers, and WonHow Does Sunshine During Pregnancy Affect Learning?
Questions and AnswersVideosLinksBook Reviews
Related Topics

ADHD: Attention Deficit Hyperactivity Disorder
Childhood Mental Disorders and Illnesses
Parenting

FDA Approves Victoza Injection for Children 10 Years and Older


HealthDay News
Updated: Jun 18th 2019

new article illustration

TUESDAY, June 18, 2019 (HealthDay News) -- Victoza (liraglutide) injection is now approved to treat type 2 diabetes in children 10 years and older, the U.S. Food and Drug Administration announced.

Approved to treat type 2 diabetes in adults in 2010, Victoza is the first noninsulin drug to be approved to treat type 2 diabetes in children since metformin in 2000. Victoza's labeling states that the injection is not a substitute for insulin and is not indicated for patients with type 1 diabetes or those with diabetic ketoacidosis. Dosage of Victoza in children should start at 0.6 mg daily for at least one week. The manufacturer's prescribing information indicates that if additional glycemic control is required, the dose should be increased to 1.2 mg daily, and then to 1.8 mg daily after at least one week of treatment with the 1.2-mg daily dose if additional control is still required.

Approval of Victoza in children aged 10 years and older was based on several placebo-controlled trials in adults and one placebo-controlled trial in children. In the trial of 134 children aged 10 years and older, at 26-week follow-up, HbA1c levels reduced to less than 7 percent for approximately 64 percent of children treated with Victoza compared with 37 percent of children treated with placebo. Researchers found similar results when patients were also taking insulin simultaneously.

Although Victoza has been indicated to reduce the risk for major adverse cardiovascular events in adults with type 2 diabetes, the FDA notes that the drug's effect on major adverse cardiovascular events in children has not been studied, and it is therefore not indicated to reduce the risk for these events in children. Children aged 10 years and older who are taking Victoza have an increased risk for hypoglycemia even without additional therapies for diabetes. Due to an increased risk for thyroid C-cell tumors, Victoza is contraindicated in patients who have had medullary thyroid carcinoma, those with family members who have had medullary thyroid carcinoma, and patients with multiple endocrine neoplasia syndrome type 2.

Approval of Victoza was granted to Novo Nordisk.

More Information